ALX Oncology
Update in progressALXO (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing cancer therapies in the United States. Its lead candidate, Evorpacept, is a CD47-blocking biologic studied as a combination therapy in gastric/GEJ cancer (ASPEN-06, Phase 2). The company collaborates with Jazz Pharmaceuticals on zanidatamab (Phase 1b/2 for breast cancer and other solid tumors), with Sanofi on isatuximab/dexamethasone (Phase 1/2 multiple myeloma), with MD Anderson on rituximab plus lenalidomide for NHL, and with Stanford for licenses. Incorporated 2015; HQ in South San Francisco, CA.
Company score
- Sentiment
- -0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.14
- Governance
- 0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Jason W. Lettmann
- Founded2015
- Employees48
- Websitewww.alxoncology.com
Identifiers
- ISINUS00166B1052
- FIGIBBG00VR8SDG8
- CUSIP00166B105
- CIK0001810182